A medicine could alleviate the ailments that anticipate the act of actual migraine and that can fat people fatal for days.
A drug already used for the acute treatment of migraine, theubrogepanthas also proven effective against the symptoms that precede hours, sometimes days the actual head pain, ailarks that can be debilitating for those suffering from this disorder. It is the first time that a medicine He manages to alleviate the ailments that anticipate migrainelike the increased sensitivity to light and sounds, nausea, mental fog and the rigidity of the neck. The results of the phase III clinical experimentation of the drug have been published on Nature Medicine.
Here we are like: headache on the way. The process of “preparation” of the migraine It starts long before the pain phase (unilateral, intense and pulsating) to the head. About 60% of patients suffering from migraine also experience the so -called prodromal phasecharacterized by symptoms such as excessive tiredness, mood changes, difficulty concentration, hyper sensitivity to some sensory stimuli, muscle rigidity. These non -painful but unpleasant ailments can last even days and are, for those who have learned to know their migraine, alarm bells of an incoming attack.
In some cases, these disorders are followed by the aura, a better, better known, of neurological phenomena of a visual, linguistic or sensory nature that precede the actual headache.
A phase not to be forgotten. It is thought that the prodromal symptoms of migraine are linked to the discomfort of the brain circuits involving the hypothalamusa small brain region that regulates many body functions. The ubrogepant blocks the receptors that bind to a molecule that makes the nerves more sensitive in the head and skull during migraine. So far, to these prodromal ailments, which make the whole experience of migraine even more unpleasant and prolonged over time, like a cycle that perpetuates over timesufficient attention had not been paid.
Drug or placebo. The neuroscientists of the King’s College London involved 438 people between 18 and 75 with migraine stories, well able to recognize the prodromes of their headache, in a 60 -day trial. The participants had to ingest a compressed of ubrogepant or a placebo (in an alternating way and without knowing what they had actually assumed) every time they warned the arrival of those family symptoms, and to report if the pill taken had some effect.
Less inconvenience. Compared to those who had taken placebo, the participants who took the drug reported a reduction in non -painful symptoms who anticipated migraine.
In the autonported assessments, the volunteers told improvements in the concentration capacity after an hour, a reduced sensitivity to light after two hours, less fatigue and less rigidity around the neck after three hours. Even the sensitivity to the sound and the sense of nausea have attenuated, while the study did not evaluate the effects on the aura, where present.
A little relief. The effects have seemed statistically contained, compared to placebo, perhaps because the ubrogepant is truly effective against migraine for about one patient every 5 – as much as the difference for this minority makes, the effect is dispersed in the data on a large group of people.
Even if the drug was already used in the acute phase, the data show that It works even better if you take it in the prodromal phase of the migraine. However, the medicine has shown its clinical potential against symptoms often so debilitating as to interfere with the normal performance of daily actions.
